Part 5/9:
The narrative around medicinal cannabis is undergoing a significant transformation thanks to scientific research. Dr. Eric Hollander, a researcher at Montefiore Medical Center in New York City, is leading pioneering clinical trials examining the efficacy of cannabis-derived compounds for autism. His focus is on Cannabidivarin (CBDV), an extract from cannabis plants similar to CBD but without the psychoactive THC component.
CBDV is believed to influence mechanisms underlying some autism behaviors, including aggression, self-injury, and repetitive actions. The research aims to understand whether cannabis compounds can address core symptoms of autism beyond anecdotal reports.